Relmada Therapeutics (RLMD) Stock Chart & Stock Price History $0.35 -0.01 (-1.41%) Closing price 01/31/2025 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.29%) As of 01/31/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Relmada Therapeutics Stock Price Performance 5 Day Performance-4.38%1 Month Performance-32.88%3 Month Performance-90.00%6 Month Performance-90.54%Year-To-Date Performance-32.88%1 Year Performance-92.35% Receive RLMD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address RLMD Stock Chart for Saturday, February, 1, 2025 RLMD Chart by TradingView Relmada Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization01/31/2025$0.35$0.35-1.41%$0.37$0.34341,645 shs$10.53 million01/30/2025$0.36$0.35-2.96%$0.37$0.34464,374 shs$10.68 million01/29/2025$0.36$0.36+0.11%$0.38$0.35639,179 shs$11.01 million01/28/2025$0.37$0.36-0.16%$0.37$0.35212,178 shs$10.99 million01/27/2025$0.39$0.37-6.22%$0.39$0.34444,250 shs$11.01 million01/24/2025$0.38$0.39+2.42%$0.40$0.37312,635 shs$11.74 million01/23/2025$0.39$0.38-2.54%$0.39$0.38135,348 shs$11.47 million01/22/2025$0.37$0.39+5.07%$0.39$0.36642,275 shs$11.77 million01/21/2025$0.37$0.37-0.72%$0.38$0.36255,494 shs$11.20 million01/20/2025$0.37$0.37$0.40$0.36208,625 shs$11.28 million Get the Latest News and Ratings for RLMD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 01/17/2025$0.38$0.37-1.66%$0.40$0.36208,625 shs$11.28 million01/16/2025$0.40$0.38-4.14%$0.41$0.36607,400 shs$11.47 million01/15/2025$0.40$0.40-0.90%$0.41$0.39262,329 shs$11.96 million01/14/2025$0.40$0.40-0.97%$0.44$0.39419,955 shs$12.07 million01/13/2025$0.41$0.40-2.04%$0.44$0.38531,247 shs$12.19 million01/10/2025$0.45$0.41-8.76%$0.45$0.40555,804 shs$12.44 million01/09/2025$0.45$0.45$0.48$0.44742,815 shs$13.64 million01/08/2025$0.47$0.45-4.76%$0.48$0.44742,815 shs$13.64 million01/07/2025$0.44$0.47+7.86%$0.49$0.43864,669 shs$14.32 million01/06/2025$0.47$0.44-6.40%$0.48$0.441.27 million shs$13.28 million01/03/2025$0.45$0.47+4.44%$0.48$0.43940,255 shs$14.19 million01/02/2025$0.52$0.45-13.44%$0.52$0.451.85 million shs$13.58 million01/01/2025$0.52$0.52$0.53$0.422.45 million shs$15.69 million12/31/2024$0.46$0.52+13.29%$0.53$0.422.45 million shs$15.69 million Related Companies vTv Therapeutics Stock Price Chart Dyadic International Stock Price Chart Tonix Pharmaceuticals Stock Price Chart Actinium Pharmaceuticals Stock Price Chart Estrella Immunopharma Stock Price Chart SCYNEXIS Stock Price Chart Iterum Therapeutics Stock Price Chart Elevation Oncology Stock Price Chart RAPT Therapeutics Stock Price Chart Barinthus Biotherapeutics Stock Price Chart Receive RLMD Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Relmada Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:RLMD) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredTrump vs. TexasEver since Donald Trump won the election, U.S. states have been rushing to pass new currency rules. These r...Stansberry Research | SponsoredTurning Panic Into OpportunityAI stocks were hammered on Jan. 27. That includes Nvidia, the undisputed leader in the artificial intellige...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
